Analyst Price Targets — EVOK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 28, 2024 2:21 pm | Yale Jen | Laidlaw | $18.00 | $7.08 | StreetInsider | Laidlaw Reiterates Buy Rating on Evoke Pharma (EVOK) |
Latest News for EVOK
William Hill owner Evoke PLC (LSE:EVOK) posted an update revealing that the past quarter was its strongest of the year, driven by gaming growth across all divisions. The bookmaker, which put itself up for sale last month after a rise in gambling taxes in the Budget, reported revenues of roughly £464 million for the fourth quarter, up 7% compared with the previous quarter but down 3% year-on-year.
Deutsche Bank has downgraded Evoke PLC (LSE:EVOK) and Rank Group PLC (LSE:RNK) to 'hold' from 'buy', slashing price targets as it reassessed the European gaming sector ahead of 2026. Evoke saw the sharpest cut.
Evoke Stockholders Received $11.00 Per Share in Cash SOLANA BEACH, Calif., and VERO BEACH, Fla.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EVOK.
U.S. House Trading
No House trades found for EVOK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.